IIQ's Principal Activity is the research and development of non-invasive diagnostic tests for early detection of cancer.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-62.98%|
INOVIQ Ltd (IIQ , formerly BARD1 Life Sciences Limited)is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
Incorporated in WA as Esmeralda Exploration Pty Ltd on 30/06/1983. Name changed to Esmeralda Exploration Ltd on 08/10/1985. Industry classification changed from 012 to 011 Gold (Gold Producer) on 08/02/2002. Name changed to Eurogold Limited on 28/05/2002.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Geoffrey A. Cumming||Non-Executive Chairman,Non-Executive Director||Jul 2020||
Mr Geoffrey A. Cumming
Non-Executive Chairman,Non-Executive Director
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Nonexecutive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd and a Nonexecutive Director of Medical Australia Ltd (ASX: MLA). Dr Cumming is the Chair of the Remuneration Committee
|Mr Tony Di Pietro||Joint Company Secretary,Chief Financial Officer||Jul 2020|
|Professor Allan Cripps||Non-Executive Director||Jan 2020||
Professor Allan Cripps
Prof Cripps is an academic, clinical scientist and health services leader, having made contributions in immunology, diagnostics, and health services delivery. From 2005 to 2016, Prof Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research Prof at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Prof Cripps had near 20 years' experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Prof Cripps is a Non-Executive Director of Neurotech International Limited (ASX: NTI). He was previously Non-Executive Director of Research Australia (2005 to 2012) and the Gold Coast Hospital and Health Services Board (2011 to 2017). Prof Cripps is a member of the Company's Remuneration Committee and Audit & Risk Committee.
|Mr Philip (Phil) John Powell||Non-Executive Director||Jun 2019||
Mr Philip (Phil) John Powell
Mr Powell is a Chartered Accountant with experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and RMA Global Ltd (ASX: RMY). He was a former Non- Executive Director of PolyNovo Ltd (ASX: PNV). Mr Powell is the Chair of the Company's Audit & Risk Committee
|Mr Robert (Max) Maxwell Johnston||Non-Executive Director||Jun 2019||
Mr Robert (Max) Maxwell Johnston
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world's largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and CentralEastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently Non-Executive Chairman of AusCann Group Holdings Ltd (ASX: AC8) and a Non-Executive Director of Medical Developments International Ltd (ASX: MVP). He was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and PolyNovo Ltd (ASX: PNV), and a former NonExecutive Chairman of Probiotec Ltd (ASX: PBP). Mr Johnston is a member of the Company's Remuneration and Audit & Risk Committees
|Dr Leearne Hinch||Chief Executive Officer||Nov 2016|
|Mrs Pauline Anne Collinson||Company Secretary||Nov 2001||
Mrs Pauline Anne Collinson
Mrs Collinson has worked for the Company for 23 years and has held the position of Company Secretary for 14 years. She is also the Company Secretary of Tanami Gold NL (ASX:TAM).
|Leearne Hinch||Chief Executive Officer||N/A|
|Dr Gregory Rice||Chief Scientific Officer||N/A|
IIQ directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|13/05/22||Philip (Phil) Powell||Buy||+20,000||$0.531||$10,620||On-market trade|
|06/05/22||Geoffrey Cumming||Buy||+32,967||$0.609||$20,082||On-market trade|
|02/05/22||Philip (Phil) Powell||Buy||+50,000||$0.58||$29,000||On-market trade|
|13/12/21||Robert (Max) Johnston||Issued||500,000||$1.04||$520,000||Issue of options|
|13/12/21||Geoffrey Cumming||Issued||500,000||$1.04||$520,000||Issue of options|
|13/12/21||Allan Cripps||Issued||500,000||$1.04||$520,000||Issue of options|
|13/12/21||Philip (Phil) Powell||Issued||500,000||$1.04||$520,000||Issue of options|
|21/10/21||Philip (Phil) Powell||Buy||+40,000||$1.092||$43,670||On-market trade|
|24/08/21||Robert (Max) Johnston||Buy||+19,354||$1.55||$29,998||Participation in share purchase plan|
|24/08/21||Philip (Phil) Powell||Buy||+19,354||$1.55||$29,998||Participation in share purchase plan|
The current holdings of IIQ directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Philip (Phil) Powell||13/05/2022||0||396,631||500,000||N/A|
|Robert (Max) Johnston||13/12/2021||N/A||404,310||500,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Moggs Creek Pty Ltd||06/09/2021||4,886,671||5.32|
|Merchant Funds Management Pty Ltd||06/09/2021||11,610,762||12.63|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|24-08-21||Merchant Funds Management Pty Ltd||25,596||14.48||12.63|
|29-07-21||Dr Irmgard Irminger-Finger||119,520,000||5.16||4.55|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.